NCT00074529CompletedPhase 2
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 512
- Primary Endpoint
- Cognitive function over 12 month period; safety and tolerability
Study Overview
Brief Summary
An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 50 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must have probable Alzheimer's disease of mild or moderate severity.
- •A brain scan and laboratory results must be consistent with Alzheimer's disease.
- •The patient must be otherwise medically healthy.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Cognitive function over 12 month period; safety and tolerability
Time Frame: over 12 month period
Secondary Outcomes
- AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.(over a 6 month and 12 month period)
Investigators
Similar Trials
Completed
Phase 2
Investigation of Memantine in the Treatment of Memory, Concentration or Attention ProblemsSubjective Cognitive ImpairmentMemory, Concentration or Attention ProblemsRetention Disorder, CognitiveMemory DisorderNCT01261741Merz Pharmaceuticals GmbH299
Completed
Phase 2
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)Alzheimer's DiseaseNCT00093951Saegis Pharmaceuticals280
Completed
Phase 2
Trial of Memantine for Cognitive Impairment in Multiple SclerosisCognition DisordersMultiple SclerosisNCT00300716Oregon Health and Science University82
Completed
Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Alzheimers Disease, FamilialAlzheimers DiseaseDementiaNCT04623242Washington University School of Medicine194
Completed
Phase 2
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseaseCentral Nervous System DiseasesCognitionAlzheimer's DiseaseNCT01073228FORUM Pharmaceuticals Inc409